Aosaikang's subsidiary signs ASKG712 project licensing agreement
I'm PortAI, I can summarize articles.
Aosaikang's holding subsidiary AskGene Pharma has signed a licensing agreement with Visara, allowing Visara to use the independently developed innovative drug ASKG712 in specific regions. This drug targets VEGF and ANG-2 and is currently undergoing Phase IIa clinical trials in China, showing good safety and efficacy. This collaboration will promote the research and commercialization of ASKG712, aligning with the company's strategic direction and is expected to have a positive impact on future performance
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments